Executive Chairman · Vertex Pharmaceuticals Inc (VRTX)

Jeffrey Leiden

A named executive officer of Vertex Pharmaceuticals in every fiscal year CompBrief holds from FY2016 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$6,595,282

Salary $0Stock awards $6,500,260

FY2022: $8,593,180

4th of 5 named executive officers at Vertex Pharmaceuticals by FY2023 total.

5 named officers on file for Vertex Pharmaceuticals, FY2023

Jeffrey Leiden’s pay file — $29

  • 8 fiscal years of pay, line by line
  • 18 equity grants, each cited to its filing
  • VRTX’s disclosed peer group of 12 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vertex Pharmaceuticals’s whole pay program stands against its peers

  • Vertex Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VRTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 4, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Jeffrey Leiden’s full pay file as a PDF — free

More than this page: up to 10 years of Jeffrey’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Jeffrey Leiden compensation by year

Vertex Pharmaceuticals Summary Compensation Table · all 8 fiscal years held
In US dollars, as Vertex Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Salary$1,300,000$1,300,000$1,300,000$1,300,000$1,121,539$242,308$0$0
Bonus$0$0$0$0$0$0$0—
Stock awards$9,800,076$8,750,114$9,800,288$9,334,681$13,335,168$7,875,259$8,500,250$6,500,260
Option awards$4,060,397$3,700,877$4,243,973$4,572,039$0$0$0—
Non-equity incentive$2,246,400$3,463,200$3,440,151$3,510,000$1,973,400$0$0$0
Pension and deferred compensation$0$0$0$0$0$0$0—
All other$12,885$13,110$14,735$73,265$43,138$39,672$92,930$95,022
Total$17,419,758$17,227,301$18,799,147$18,789,985$16,473,245$8,157,239$8,593,180$6,595,282

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vertex Pharmaceuticals Inc DEF 14A filed April 4, 2024, accession 0001308179-24-000452, and prior-year filings.

How this page was built: the Vertex Pharmaceuticals Inc filed document, accession 0001308179-24-000452. Every figure is read from that document and cited to the page and table it appears in. Filed April 4, 2024.

$17.4M
$17.2M
$18.8M
$18.8M
$16.5M
$8.2M
$8.6M
$6.6M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU28,444$6,246,302—
RSU20,928$4,595,789—
PSU15,731$3,454,528—
PSU10,464$2,297,894—

Per the Outstanding Equity Awards at Fiscal Year-End table in Vertex Pharmaceuticals Inc's FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

35 Form 4 lines since the FY2023 proxy (filed April 4, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-02-24Tax withholding—3,547$485.1134,797
2026-02-18Tax withholding—2,964$483.7538,344
2026-02-17Grant or award—8,269$0.0041,308
2026-01-22Grant or award—9,012$0.0033,039
2025-12-04Exercise or conversion10b5-11$91.0524,027
2025-12-04Exercise or conversion derivative10b5-11$0.000
2025-12-03Sale10b5-12,070$455.2224,026
2025-12-03Sale10b5-17,899$445.5667,298

The 8 most recent of 35 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Vertex Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Reshma KewalramaniChief Executive Officer and President$20,594,441
Stuart ArbuckleExecutive Vice President and Chief Operating Officer$8,998,949
Charles WagnerExecutive Vice President and Chief Financial Officer$7,371,751
Jeffrey Leiden · this pageExecutive Chairman$6,595,282
David AltshulerExecutive Vice President and Chief Scientific Officer$6,541,100

Board service

Vertex Pharmaceuticals board · FY2021–FY2024

How this board is paid

Company policy: Vertex Pharmaceuticals pays directors a $100,000 cash retainer and $400,000 in Options, RSUs, or 50/50 mix. As stated in Vertex Pharmaceuticals's FY2024 proxy.

The full Vertex Pharmaceuticals compensation record

free company brief

This page is one person within Vertex Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Vertex Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vertex Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jeffrey Leiden's compensation dossier · One-time report. No refunds.